NCT00747006 - Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

February 28, 2011

Study Completion Date

May 31, 2011

Conditions

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1

Interventions

DRUG

TI Inhalation Powder and Humalog (Amendment 1)

Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.

DRUG

TI Inhalation Powder (original protocol)

Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics

Trial Locations (1)

93105

Sansum Medical Research Institute, Santa Barbara